Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Pulmonary Drugs Market?

The market size of pulmonary drugs has seen a consistent rise in the past few years. Its growth is expected to march forward from $54.28 billion in 2024 to $56.98 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.0%. The significant growth witnessed in the historic period can be credited to the escalating incidence of respiratory diseases, a surge in smoking rates, an augmenting elderly population, wider accessibility to healthcare services, and rising pollution levels.

Expectations are high for the pulmonary drugs market as it’s predicted to experience robust growth in the coming years. The market is projected to increase to $70.35 billion by 2029, with a compound annual growth rate (CAGR) of 5.4%. The driving factors for this growth during the forecast period comprise of an enhanced healthcare infrastructure, an escalation in cardiovascular disease cases, the extension of homecare treatments, heightened awareness of pulmonary diseases, and a surge in asthma cases. The major trends to be seen during this forecast period encompassed technological evolution, the use of artificial intelligence in drug discovery, an increase in the use of smart inhalers, advancements in nanotechnology-based formulations, and progress in gene therapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What Underlying Factors Are Supporting The Pulmonary Drugs Market Growth?

The escalating frequency of disorders related to the respiratory system is predicted to drive the expansion of the pulmonary drugs market. These medical issues, which impact the lungs and breathing passages, hinder the usual capacity to breathe and exchange oxygen. Due to the increasing prominence of smoking habits, such disorders are on the rise, leading to harmful impacts on the lungs and chronic diseases. Pulmonary medication plays an integral part in managing these issues by enhancing lung operation, lowering inflammation, and easing obstruction in the airway for improved breathing. For instance, the Bureau of Labor Statistics, a government agency in the United States, noted in November 2023 that the rate of sickness among private industry employers increased from 37.7 cases in 2021 to 45.2 cases per 10,000 FTE employees in 2022. This increase was primarily due to a higher incidence of respiratory problems, which went up from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Hence, the escalating respiratory disorders are contributing to the growth of the pulmonary drugs market.

Which Sub-Segments Are Driving Growth Within The Pulmonary Drugs Market?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Future-Focused Trends Are Anticipated In The Pulmonary Drugs Market?

Focusing on the latest drug innovations such as Single-Inhaler Triple Therapy (SITT), prominent companies in the pulmonary drugs market aim to improve the effectiveness of treatments, increase patient compliance, and facilitate simpler medication schedules for improved disease management. SITT is an advanced treatment strategy that integrates three distinct medications into one inhaler for a more effective management of chronic respiratory ailments like Chronic Obstructive Pulmonary Disease (COPD). For example, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, a pharmaceutical firm based in India, rolled out India’s first SITT, Trelegy Ellipta, meant for patients with COPD. This treatment employs fluticasone furoate, umeclidinium, and vilanterol to better lung functionality and decrease symptom flare-ups. The forward-thinking Ellipta inhaler guarantees correct dosage and increases patient compliance when compared to multiple-inhaler therapies. This introduction seeks to streamline treatment and enhance patient results, given that over 100 million COPD patients exist in India.

Who Are The Dominant Players In The Pulmonary Drugs Market Today?

Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

How Do Regional Dynamics Influence The Pulmonary Drugs Market Performance?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model